Viewing Eye Care Network
News|Articles|October 10, 2026

From gene therapy to restoring sight: Highlights from EURETINA 2026

Key takeaways on gene therapy, GA, sustained delivery and AI in Vienna

Gene therapies nearing phase 3 readouts, cell and optogenetic therapies aimed at restoring vision, and new data on sustained drug delivery were among the topics at the 26th EURETINA Congress, held 1–4 October 2026 in Vienna, Austria.

Speakers shared updates in their sessions and in interviews with Ophthalmology Times Europe, including on geographic atrophy (GA) and artificial intelligence (AI). In case you missed it, here are highlights from our EURETINA 2026 coverage.

>>> See all of our EURETINA 2026 coverage.

Gene therapy and sustained delivery

Arshad Khanani, MD, FASRS, of Sierra Eye Associates, reviewed three gene therapy programmes for neovascular age-related macular degeneration (nAMD) in phase 3 development, all expected to read out within 12 months: surabgene lomparvovec (AbbVie and REGENXBIO), 4D-150 (4D Molecular Therapeutics) and ixoberogene soroparvovec (Adverum Biotechnologies). “The bottom line is that gene therapy for neovascular AMD is close to being a reality for our patients,” he said. Khanani also reported 2-year SPECTRA (NCT05930561) results for 4D-150 in diabetic macular oedema (DMO), with no intraocular inflammation after a single injection.

Roger A. Goldberg, MD, MBA, of Bay Area Retina Associates, presented top-line results from LUGANO (NCT06668064), a phase 3 trial of a vorolanib intravitreal insert (Duravyu; EyePoint Pharmaceuticals) dosed every 6 months in nAMD. The trial missed its noninferiority endpoint, with a 3.8-letter difference in visual acuity gain favouring aflibercept, which Goldberg attributed to nine patients—all in the insert arm—who lost vision from causes other than nAMD.

Anatomic control was comparable between arms, and the insert reduced treatment burden by 42%. Katherine Talcott, MD, of the Cole Eye Institute, Cleveland Clinic, reported that the same insert reduced the need for supplemental treatment in the phase 2 VERONA study (NCT06099184) in DMO, with vision and anatomic gains seen as early as 1 month.

Geographic atrophy and restoring vision

Francesca Cordeiro, PhD, MD, FRCOphth, of Imperial College London, discussed newly published data showing that a single baseline Detection of Apoptosing Retinal Cells test predicted how fast and in which direction GA would grow over up to about 4 years. She said the approach could help clinicians decide whom to treat before vision loss occurs.

Ritesh Narula, MBBS, MS, of LV Prasad Eye Institute, reported that subretinal retinal pigment epithelium cell therapy (Eyecyte-RPE; Eyestem) produced a mean gain of about 11 letters in advanced GA in phase 1, maintained at about 18 months, with similar early gains in the ongoing phase 2 trial. One case of endophthalmitis and one macular hole have occurred in phase 2.

Jordi Monés, MD, PhD, of the Institut de la Màcula in Barcelona, Spain, presented the rationale for sonpiretigene isteparvovec (MCO-010; Nanoscope Therapeutics), a gene-agnostic optogenetic therapy that makes retinal bipolar cells sensitive to light. After vision gains in retinitis pigmentosa and Stargardt disease, a phase 2 trial is planned in Stargardt disease and GA. “Improving vision is something that we could not imagine a few years ago,” he said.

Medical retina

Elon van Dijk, MD, PhD, FEBOphth, of the Rotterdam Eye Hospital and Leiden University Medical Center, reviewed randomized trial evidence in chronic central serous chorioretinopathy. Half-dose photodynamic therapy (PDT) outperformed both micropulse laser and eplerenone, which he said has no place in treating the disease. He urged colleagues to “try everything you can to make PDT available in your country.”

Serena Salvatore, MD, of Bristol Eye Hospital, UK, co-chaired a symposium on retinal laser. “Laser has quietly become the procedure we assume everyone can do and nobody is quite sure who taught them,” she said, adding that laser and anti-VEGF therapy are “partners, not rivals.”

Surgery

In the Kreissig Award Lecture, David Steel, MBBS, FRCOphth, MD(Res), a consultant vitreoretinal surgeon at Sunderland Eye Infirmary and honorary professor of retinal surgery at Newcastle University, UK, drew on the British and Eire Association of Vitreoretinal Surgeons and EURETINA vitreoretinal outcomes database. When silicone oil was used, heavy oil doubled the odds of surgical success compared with light oil, and C2F6 gas appeared to offer small anatomical and visual advantages over SF6 and C3F8.

AI and genetics

Paul Nderitu, MBChB, MPhil, MBCS, FRCOphth, PhD, of UCL and Moorfields, said Global RETFound, an effort to build a global foundation model for retinal imaging, now includes 108 partners from more than 40 countries. The team aims to make the model open access for research.

João Pedro Marques, MD, MSc, PhD, FEBOphth, of Unidade Local de Saúde de Coimbra, Portugal, described Portugal’s national inherited retinal disease registry, which holds about 2,400 patients, more than 65% of the country’s expected total. “If you don’t have genetic testing, if you don’t map your patients, you don’t know which patients to treat,” he said.


Related to this article